SCHEMBL8799197

SCHEMBL8799197

COc1ccc2sc(=O)[nH]c2c1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE3B Q13370 3/20 0.77
PDE3A Q14432 3/20 0.77
PSMB8 P28062 2/20 0.65
CMA1 P23946 1/20 0.56
KDM4E B2RXH2 5/20 0.47
ALDH1A1 P00352 5/20 0.46
HPGD P15428 4/20 0.46
HTT P42858 2/20 0.46
NPSR1 Q6W5P4 2/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
HCRTR1 O43613 1/20 0.46
CYP1A2 P05177 1/20 0.46
PPARG P37231 1/20 0.46
NCOA2 Q15596 1/20 0.46
NCOA1 Q15788 1/20 0.46
RXFP1 Q9HBX9 1/20 0.46
NCOA3 Q9Y6Q9 1/20 0.46
MAPT P10636 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1848088 0.87 PDE3B (1.00) PDE3BPDE3APSMB8CMA1KDM4E
SCHEMBL30613131 0.79 PSMB8 (1.00) PDE3BPDE3APSMB8KDM4EALDH1A1
SCHEMBL23536160 0.79 PSMB8 (1.00) PDE3BPDE3APSMB8KDM4EALDH1A1
SCHEMBL11107086 0.78 CMA1 (0.51) PDE3BPDE3APSMB8CMA1HTT
SCHEMBL9685722 0.78 PDE3B (0.76) PDE3BPDE3APSMB8KDM4EALDH1A1
SCHEMBL30613137 0.77 TDP1 (0.49) PDE3BPDE3APSMB8CMA1KDM4E
SCHEMBL11544669 0.76 PDE3B (0.68) PDE3BPDE3APSMB8KDM4EALDH1A1
SCHEMBL8286761 0.76 CMA1 (0.61) PDE3BPDE3ACMA1ALDH1A1
SCHEMBL11540998 0.75 PSMB8 (0.59) PDE3BPDE3APSMB8KDM4EALDH1A1
SCHEMBL11541002 0.75 PSMB8 (0.59) PDE3BPDE3APSMB8KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0039440-B1 MEDICINES CONTAINING SUBSTITUTED BENZOTHIAZOL-2-(3H)-ONES Dr. Karl Thomae GmbH (DE) 1983-06-22 EP claimed
US-4353919-A Analgesic and antipyretic pharmaceutical compositions containing a benzothiazol-2(3H)-one DR. KARL THOMAE GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1982-10-12 US claimed
EP-0039440-A1 Medicines containing substituted benzothiazol-2-(3H)-ones Dr. Karl Thomae GmbH (DE) 1981-11-11 EP claimed
EP-4524139-A1 IMIDAZOPYRIDAZINE SUBSTITUTED BENZENE RING DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE Shanghai Simr Biotechnology Co., Ltd. (CN) 2025-03-19 EP disclosed
US-20240294482-A1 METHOD FOR CATALYTICALLY ACTIVATING CARBON DIOXIDE AS CARBONYLATION REAGENT WITH INORGANIC SULFUR INNER MONGOLIA UNIVERSITY OF TECHNOLOGY (CN) 2024-09-05 US disclosed
CN-117820253-A 3, 6-disubstituted benzothiazole compound and synthesis and application thereof 西北农林科技大学 2024-04-05 CN disclosed
CN-117069725-A Imidazopyridazine substituted benzene ring derivative, preparation method, pharmaceutical composition and application 上海赛默罗生物科技有限公司 2023-11-17 CN disclosed
WO-2023216753-A1 IMIDAZOPYRIDAZINE SUBSTITUTED BENZENE RING DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE 上海赛默罗生物科技有限公司 2023-11-16 WO disclosed
CN-116947843-A 3, 5-disubstituted benzothia (oxa) azole compounds, synthesis and application thereof 西北农林科技大学 2023-10-27 CN disclosed
CN-116745273-A Method for catalyzing and activating carbon dioxide by using inorganic sulfur as carbonylation reagent 内蒙古工业大学 2023-09-12 CN disclosed
CN-115246795-A Isoxazoline compound with 4-phenyl para-position containing ether structure, preparation thereof and application thereof as insecticide and bactericide 瑞普(天津)生物药业有限公司 2022-10-28 CN disclosed
US-5326775-A Treating sleep disorders ADIR ET COMPAGNIE (FR) 1994-07-05 US disclosed
US-5322843-A Treating sleep disorders ADIR ET COMPAGNIE (FR) 1994-06-21 US disclosed
US-5322849-A Treating sleep disorders ADIR ET COMPAGNIE (FR) 1994-06-21 US disclosed
US-5300507-A Treating sleep disorders ADIR ET COMPAGNIE (FR) 1994-04-05 US disclosed
US-5240919-A Treating sleep disorders ADIR ET COMPAGNIE (FR) 1993-08-31 US disclosed
EP-0506539-A1 Heterocyclic alkylamides, process for their preparation and pharmaceutical compositions containing them ADIR ET COMPAGNIE (FR) 1992-09-30 EP disclosed
EP-0039440-B1 MEDICINES CONTAINING SUBSTITUTED BENZOTHIAZOL-2-(3H)-ONES Dr. Karl Thomae GmbH (DE) 1983-06-22 EP disclosed
US-4353919-A Analgesic and antipyretic pharmaceutical compositions containing a benzothiazol-2(3H)-one DR. KARL THOMAE GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1982-10-12 US disclosed
EP-0039440-A1 Medicines containing substituted benzothiazol-2-(3H)-ones Dr. Karl Thomae GmbH (DE) 1981-11-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240294482-A1 METHOD FOR CATALYTICALLY ACTIVATING CARBON DIOXIDE AS CARBONYLATION REAGENT WITH INORGANIC SULFUR TST, CBR3, SMOX PDE3B 4085/4885PDE3A 4059/4885PSMB8 3331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.